Luncheon

Oct. 12 (Wed.) ,2016 11:45-12:45

Annex Hall
F201

Drug and Drug Discovery

Embassy of Canada in Japan

7th Canada Life Sciences Seminar "Opportunities in Canada - Forefront of Cancer Immunotherapy Development"

Canada invests approximately C$1 billion in life sciences research annually, resulting in an innovative and dynamic biotech startup space. This seminar features two biotech companies developing cancer immunotherapies.
Zenith is conducting Phase I study of a highly potent and selective bromodomain inhibitor, ZEN 3694 for prostate cancer. This seminar will focus on the interim data of the trial and the potential of ZEN3694.
Over the last 2 years, Telesta has focused on Phase III studies for Mycobacterium phlei Cell Wall-Nucleic Acid Complex (MCNA) for bladder cancer. The seminar will provide an overview of key events over the course of MCNA’s development leading up to the BLA submission. The presentation will also touch on Telesta’s recent acquisition agreement with Prometic.

Clinical Development of a Novel Bromodomain Inhibitor for Solid Tumors: Epigenetic Modulation for Immuno-oncology Applications

Sanjay Lakhotia

Chief Business Officer, Zenith Epigenetics Corporation

MCNA from Concept to BLA – the Path to Building a Canadian-Based Company with Global Aspirations

Mathieu Boudreau

Vice President, Corporate Development & Licensing, Telesta Therapeutics

Close Window